[Anti-viral injectable treatment (cidofovir) in laryngeal papillomatosis].
Laryngeal papillomatosis, due to type 6 and 11 papova-virus A, causes devastating lesions leading to difficult clinical situations (severe dysphonia, or laryngeal dyspnea). Recurrence requires repeated endoscopy with CO2 laser treatment to keep the airways free and prevent the lesions spreading. In patients presenting aggressive papillomatosis, such repeated intervention causes irreversible lesions which have a very negative impact on the vocal prognosis. In this context, developing a form of minimally invasive surgery would help avoid vocal sequelae as far as possible. Thus, anti-viral agents can be injected directly into the lesion per-operatively so as best to preserve the healthy mucosa and muscles, thereby managing the lesions with precision and less iatrogenic impact than with CO2 laser. Twenty six patients since 1998 have undergone Cidofovir endoscopy. Total remission was achieved in eight of them (31%), after between two and eight interventions. Twenty seven (65%) showed clinically significant partial remission. Such positive results were obtained in both adults and children. Associated lesion excision was required in cases of obstructive or persistent papilloma. Intralesion Cidofovir injection thus seems to have proved highly effective in the clinical management of laryngeal papillomatosis. Combined Cidovir injection and surgical excision remains necessary in case of large or persistent papillomas. These results have lead us to indicate this procedure as primary treatment for laryngeal papillomatosis in adults and children.
Hôpital Universitaire Edouard Herriot, Pavillon U, 5 Pl d'Arsonval, F-69437 Lyon, France.
B
B
Coulombeau
A
A
Nusa Naiman
P
P
Ceruse
P
P
Froehlich
D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D000077404:Cidofovir; D003131:Combined Modality Therapy; D003596:Cytosine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000601:surgery / Q000821:virology; D007828:Laryngoscopy; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D027383:Papillomaviridae / Q000187:drug effects*; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000601:surgery / Q000821:virology; D011446:Prospective Studies; D016896:Treatment Outcome; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000601:surgery / Q000821:virology
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir